Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase

Clinical Microbiology and Infection

Volumn 10, Issue 9, 2004, Pages 857-860

  Fritsche, Thomas R ^a   Moet, G J ^a   Jones, R N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Broth microdilution panels; LBM 415; MIC testing; NVP PDF 713; Peptide inhibitor

Indexed keywords

METICILLIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLINICAL TRIAL; CULTURE MEDIUM; DILUTION; ENTEROCOCCUS; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; VALIDATION PROCESS;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 4644240824     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1198-743X.2004.00946.x     Document Type: Article

References (9)

1. Gilglione C, Pierre M, Meinnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol 2000; 36: 1197-1205.
2. Apfel CM, Locher H, Evers S et al. Peptide deformylase as an antimicrobial drug target: target validation and resistance development. Antimicrob Agents Chemother 2001; 45: 1058-1064.
3. Clements JM, Beckett RP, Brown A et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 2001; 45: 563-570.
4. Wise R, Andrews JM, Ashby J. In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 1117-1118.
5. Jones RN, Rhomberg PR. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother 2003; 51: 157-161.
6. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A2. Wayne, PA: NCCLS, 2001.
7. Anderegg TR, Biedenbach DJ, Jones RN. The Quality Control Working Group. Quality control guidelines for MIC susceptibility testing of NVP PDF-713, a novel peptide deformylase inhibitor. Int J Antimicrob Agents 2004; 22: 84-86.
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standard. Wayne, PA: NCCLS, 2003.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 13th informational supplement. M100-S13. Wayne, PA: NCCLS, 2003.